Clinical trial
Metazym for the Treatment of Patients With Late Infantile Metachromatic…
NCT00418561 · Shire, Industry · Completed
Key facts
| NCT number | NCT00418561 |
|---|---|
| Title | Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) |
| Official title | A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metachromatic Leukodystrophy (MLD) |
| Intervention type | Biological |
| Interventions | rhASA - Dose Level 1, rhASA - Dose Level 2, rhASA - Dose Level 3 |
| Enrollment | 13 |
| Start date | Jan 22, 2007 |
| Primary completion | Mar 27, 2008 |
| Completion | Mar 27, 2008 |
| First posted | Jan 5, 2007 |
| Last update posted | Jun 25, 2021 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: